News
Videos
Conferences
Events
Resources
Subscribe

News|Videos|June 17, 2024

Treatment Option for Polycythemia Vera

Author(s)Sponsored Content

Newsletter

Stay up to date on cancer updates, research and education

Related Content

The Caregiver’s Compass: Guiding Your Loved One Through Advanced NSCLC

February 4th 2026

The NCCN Clinical Practice Guidelines in Oncology now include Besremi as a Category 1 preferred treatment option for some with high-risk essential thrombocythemia: © stock.adobe.com.

Besremi Recognized by Updated Guidelines for Essential Thrombocythemia

January 28th 2026

Stage 2 essential thrombocythemia is a slow-growing blood cancer managed with monitoring or treatment to reduce clot risk and control symptoms.

Helping You Understand Stage 2 Essential Thrombocythemia

January 25th 2026

The FDA has granted orphan drug designation to zavabresib, an investigational therapy for the treatment of myelofibrosis, a rare blood cancer: © stock.adobe.com.

FDA Orphan Drug Designation Granted to Zavabresib for Myelofibrosis

January 22nd 2026

Image of "FDA"

FDA Accepts Besremi Application for Essential Thrombocythemia

BySpencer Feldman

January 13th 2026

Trending on CURE

How to Become a Cancer Survivor and Transforming Patients into People

Immunotherapy Combo Shows Potential Progress in Some Pancreatic Cancers

New Combination Treatment Approach Studied in Pancreatic Cancer

NCCN Names Trodelvy a Preferred First-Line Treatment for Metastatic TNBC

Pastina Bean Soup Supports Nutrition in Colorectal Cancer Care